Background: This study aims to explore the role of low-dose rivaroxaban (≤10 mg daily) for the treatment of atherosclerotic cardiovascular disease (ASCVD). Methods: PubMed, Embase and the Cochrane Library were searched for randomized controlled trials (RCTs) of low-dose rivaroxaban in patients with ASCVD including coronary artery disease (CAD) and peripheral artery disease (PAD). Literature screening, data extraction, and risk of bias assessment were carried out independently by two researchers. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random-effect models to determine risks of outcomes in ASCVD patients treated with rivaroxaban and comparators, and meta-analysis was conducted via Review Manager 5.3.5 software. Results: 3,768 records were obtained through literature search, and 9 articles representing 6 RCTs ultimately qualified for this study. The meta-analysis indicated that for patients with CAD, the addition of rivaroxaban (5 mg daily) to aspirin could significantly reduce the risk of major adverse cardiovascular events (MACEs) compared with aspirin alone (HR 0.81, 95% CI, 0.72 to 0.91, p = 0.0004, I2 = 60%, 4 studies). For PAD patients receiving rivaroxaban (5 mg daily) plus aspirin, there was no significant reduction in the risk of MACEs (HR 0.84, 95% CI, 0.63 to 1.13, p = 0.25, I2 = 74%, 2 studies); however, there was significant reduction in major adverse limb events (MALEs) (HR 0.54, 95% CI, 0.35 to 0.83, p = 0.005, one studies) and in the composite of MACEs or MALEs (HR 0.78, 95% CI, 0.64 to 0.95, p = 0.02, I2 = 66%, 2 studies) when compared with patients receiving aspirin alone. Meanwhile, rivaroxaban combined with aspirin significantly increased the risk of International Society on Thrombosis and Haemostasis (ISTH) major bleeding compared with aspirin alone in patients with CAD (HR 1.74, 95% CI, 1.43 to 2.13, p < 0.00001, I2 = 0%, 2 studies) and PAD (HR 1.47, 95% CI, 1.19 to 1.83, p = 0.0004, I2 = 0%, 2 studies). Conclusions: Compared with standard antiplatelet therapy, the addition of a 5 mg daily dose of rivaroxaban to standard antiplatelet therapy may improve cardiovascular or limb outcomes of patients with ASCVD, with an increase in major bleeding. Patients who would benefit from the addition of low-dose rivaroxaban to antiplatelet agents and appropriate dual-pathway antithrombotic strategies should be identified in clinical practice to individualize antithrombotic therapy.
Background: This study aims to explore the role of low-dose rivaroxaban (≤10 mg daily) for the treatment of atherosclerotic cardiovascular disease (ASCVD). Methods: PubMed, Embase and the Cochrane Library were searched for randomized controlled trials (RCTs) of low-dose rivaroxaban in patients with ASCVD including coronary artery disease (CAD) and peripheral artery disease (PAD). Literature screening, data extraction, and risk of bias assessment were carried out independently by two researchers. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random-effect models to determine risks of outcomes in ASCVD patients treated with rivaroxaban and comparators, and meta-analysis was conducted via Review Manager 5.3.5 software. Results: 3,768 records were obtained through literature search, and 9 articles representing 6 RCTs ultimately qualified for this study. The meta-analysis indicated that for patients with CAD, the addition of rivaroxaban (5 mg daily) to aspirin could significantly reduce the risk of major adverse cardiovascular events (MACEs) compared with aspirin alone (HR 0.81, 95% CI, 0.72 to 0.91, p = 0.0004, I2 = 60%, 4 studies). For PAD patients receiving rivaroxaban (5 mg daily) plus aspirin, there was no significant reduction in the risk of MACEs (HR 0.84, 95% CI, 0.63 to 1.13, p = 0.25, I2 = 74%, 2 studies); however, there was significant reduction in major adverse limb events (MALEs) (HR 0.54, 95% CI, 0.35 to 0.83, p = 0.005, one studies) and in the composite of MACEs or MALEs (HR 0.78, 95% CI, 0.64 to 0.95, p = 0.02, I2 = 66%, 2 studies) when compared with patients receiving aspirin alone. Meanwhile, rivaroxaban combined with aspirin significantly increased the risk of International Society on Thrombosis and Haemostasis (ISTH) major bleeding compared with aspirin alone in patients with CAD (HR 1.74, 95% CI, 1.43 to 2.13, p < 0.00001, I2 = 0%, 2 studies) and PAD (HR 1.47, 95% CI, 1.19 to 1.83, p = 0.0004, I2 = 0%, 2 studies). Conclusions: Compared with standard antiplatelet therapy, the addition of a 5 mg daily dose of rivaroxaban to standard antiplatelet therapy may improve cardiovascular or limb outcomes of patients with ASCVD, with an increase in major bleeding. Patients who would benefit from the addition of low-dose rivaroxaban to antiplatelet agents and appropriate dual-pathway antithrombotic strategies should be identified in clinical practice to individualize antithrombotic therapy.
Authors: Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson Journal: N Engl J Med Date: 2011-11-13 Impact factor: 91.245
Authors: Roxana Mehran; Usman Baber; Samin K Sharma; David J Cohen; Dominick J Angiolillo; Carlo Briguori; Jin Y Cha; Timothy Collier; George Dangas; Dariusz Dudek; Vladimír Džavík; Javier Escaned; Robert Gil; Paul Gurbel; Christian W Hamm; Timothy Henry; Kurt Huber; Adnan Kastrati; Upendra Kaul; Ran Kornowski; Mitchell Krucoff; Vijay Kunadian; Steven O Marx; Shamir R Mehta; David Moliterno; E Magnus Ohman; Keith Oldroyd; Gennaro Sardella; Samantha Sartori; Richard Shlofmitz; P Gabriel Steg; Giora Weisz; Bernhard Witzenbichler; Ya-Ling Han; Stuart Pocock; C Michael Gibson Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: John W Eikelboom; Jacqueline J Bosch; Stuart J Connolly; Olga Shestakovska; Gilles R Dagenais; Robert G Hart; Darryl P Leong; Martin O'Donnell; Keith A A Fox; Deepak L Bhatt; John A Cairns; Christoph Tasto; Scott D Berkowitz; Nancy Cook Bruns; Eva Muehlhofer; Rafael Diaz; Aldo P Maggioni; Salim Yusuf Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Ashlei C Beiswenger; Alice Jo; Karem Harth; Norman H Kumins; Mehdi H Shishehbor; Vikram S Kashyap Journal: J Vasc Surg Date: 2018-06 Impact factor: 4.268
Authors: Pedro A Villablanca; David Holmes; Divyanshu Mohananey; David F Briceno; Ivan J Núñez Gil; Faraj Kargoli; Tanush Gupta; Jorge R Kizer; Anna E Bortnick; Jose Wiley; Mark A Menegus; Robert Pyo; Mario García; Harish Ramakrishna; Farouk Mookadam Journal: Coron Artery Dis Date: 2017-08 Impact factor: 1.439
Authors: E G Bovill; M L Terrin; D C Stump; A D Berke; M Frederick; D Collen; F Feit; J M Gore; L D Hillis; C T Lambrew Journal: Ann Intern Med Date: 1991-08-15 Impact factor: 25.391
Authors: William R Hiatt; F Gerry R Fowkes; Gretchen Heizer; Jeffrey S Berger; Iris Baumgartner; Peter Held; Brian G Katona; Kenneth W Mahaffey; Lars Norgren; W Schuyler Jones; Juuso Blomster; Marcus Millegård; Craig Reist; Manesh R Patel Journal: N Engl J Med Date: 2016-11-13 Impact factor: 91.245
Authors: A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin Journal: J Am Coll Cardiol Date: 1988-01 Impact factor: 24.094
Authors: Jonas Oldgren; Lars Wallentin; John H Alexander; Stefan James; Birgitta Jönelid; Gabriel Steg; Johan Sundström Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983